tiprankstipranks
Trending News
More News >
Ribomic, Inc. (JP:4591)
:4591
Japanese Market

Ribomic, Inc. (4591) Price & Analysis

Compare
0 Followers

4591 Stock Chart & Stats


Financials

4591 FAQ

What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥60.00 and its highest was ¥141.00 in the past 12 months.
    What is Ribomic, Inc.’s market cap?
    Ribomic, Inc.’s market cap is ¥5.09B.
      When is Ribomic, Inc.’s upcoming earnings report date?
      Ribomic, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 31 days.
        How were Ribomic, Inc.’s earnings last quarter?
        Ribomic, Inc. released its earnings results on May 13, 2025. The company reported -¥6.33 earnings per share for the quarter, missing the consensus estimate of N/A by -¥6.33.
          Is Ribomic, Inc. overvalued?
          According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Ribomic, Inc. pay dividends?
            Ribomic, Inc. does not currently pay dividends.
            What is Ribomic, Inc.’s EPS estimate?
            Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Ribomic, Inc. have?
            Ribomic, Inc. has 44,613,940 shares outstanding.
              What happened to Ribomic, Inc.’s price movement after its last earnings report?
              Ribomic, Inc. reported an EPS of -¥6.33 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.
                Which hedge fund is a major shareholder of Ribomic, Inc.?
                Currently, no hedge funds are holding shares in JP:4591

                Company Description

                Ribomic, Inc.

                Ribomic, Inc. (4591) is a biotechnology company specializing in the development of aptamer-based therapeutics. Aptamers are short, single-stranded DNA or RNA molecules that can bind to specific targets, such as proteins, with high affinity and specificity. Ribomic focuses on creating innovative treatments for a variety of diseases, including ocular disorders, through its proprietary RiboART platform. The company operates within the pharmaceutical and biotechnology sectors, advancing its pipeline of products towards clinical trials and potential commercialization.
                Similar Stocks
                Company
                Price & Change
                Follow
                Otsuka Holdings Co
                Astellas Pharma
                Eisai Co
                Takeda Pharmaceutical Co
                AnGes
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis